A groundbreaking blood test that detects a protein linked to Alzheimer’s could identify the disease up to a decade before symptoms appear, according to a study presented at the Alzheimer’s Association International Conference.The test measures levels of p-tau217, a protein fragment associated with neurodegeneration.

Researchers found that individuals with very high levels of this protein had a 38% risk of developing cognitive impairment within five years, rising to 78% over a decade.Conversely, those with low levels were unlikely to progress, similar to the general population’s risk.

The study, involving 2,684 participants, could revolutionize early intervention strategies by enabling targeted clinical trials for potential treatments.

While the test doesn’t offer a cure, it provides critical data for drug development, allowing researchers to enroll high-risk individuals in prevention studies.

Experts like Reisa Sperling and Jessica Langbaum hailed the discovery as a 'game changer,' emphasizing its potential to streamline Alzheimer’s research and improve patient outcomes.However, ethical considerations around early diagnosis and psychological impact remain under discussion.